Detection of aberrant DNA methylation in bladder cancer
INTRODUCTION
Bladder cancer is the ninth most common cancer in the world, with an estimated 430,000 new cases and 165,000 deaths in 2012 [1] [2] [3] . In the US alone, 76,960 new cases are expected to occur in 2016, and 16,390 bladder cancer patients are expected to die from the disease in the same year [4] . The vast majority (>90%) of bladder cancer cases are urothelial carcinomas.
Approximately 75% of patients are diagnosed with non-muscle-invasive bladder cancer, of which roughly 50% are of low-grade [1, 3] . The prognosis of these non-invasive tumors is usually favorable; however, up to 80% of cases will recur after complete transurethral resection, and up to 45% of cases will progress to invasive cancer within 5 years [5, 6] . Cystoscopy, followed by biopsy of suspicious lesions, remains the gold standard for detection of both new and recurrent bladder cancer. However, this approach is highly invasive and costly and its sensitivity can be as low as 60% for detection of carcinoma in situ [6, 7] . Non-invasive tests for bladder cancer diagnosis are available and include voided urine cytology, cytogenetic analysis by fluorescence in situ hybridization, and detection of genetic mutations in urine. Yet, these tests have limited sensitivities (54-86%), and specificities (61-90%), and often yield false positive results [3, 6, 8] . Given the high recurrence rate of bladder cancer and the costs and discomfort associated with post-diagnosis follow-ups, the quest for novel non-invasive tests to improve early detection and assist with surveillance is currently a top research priority [8, 9] .
Unlike other types of human cancer with unknown or less well-defined etiologic agent(s), bladder cancer is primarily linked to exposure to aromatic amines, a family of chemicals present in tobacco smoke and various industrial products and workplace settings [10] [11] [12] [13] . Epidemiologic studies have shown that smokers have 2-to 6-fold higher risk of bladder cancer relative to nonsmokers [1, 14] . Also, those who smoke black (air-cured) tobacco products are at increased risk of bladder cancer compared to those who smoke blond tobacco (flue-cured) products. The latter is consistent with the higher content of aromatic amines in smoke from black tobacco products relative to blond tobacco products [11] . Furthermore, higher incidence of bladder cancer has been observed in industrial workers exposed to aromatic amines generated during the manufacture or processing of a variety of products, including rubber, cable, textile, dye, paints, solvents, leather dust, inks, etc [10] [11] [12] [13] 15] . Lifestyle choices, such as the use of hair dyes containing aromatic amines, have also been suggested as a potential determinant of bladder cancer, although conclusive evidence is yet to emerge [15] .
Aromatic amines are known to induce DNA damage and mutations that may cause disruption of key biological pathways that may lead to cell transformation, e.g., in normal urothelium [9, 11, 16, 17] . In addition to having a genotoxic mode of action, aromatic amines, like many other chemical carcinogens, may also exert epigenetic effects of relevance to bladder carcinogenesis [6, [18] [19] [20] . Epigenetics is a fast growing field in cancer biology with tremendous potential for environmental, clinical, and translational research [21] [22] [23] . Epigenetic effects are defined as heritable changes in gene expression that do not involve alterations in the underlying DNA sequence. Aberrant DNA methylation associated with transcriptional deregulation of cancer-related genes is the best-studied epigenetic mechanism of carcinogenesis [23] [24] [25] [26] [27] [28] .
Aberrancies in DNA methylation patterns commonly occur in the early stages of carcinogenesis and as such, are detectable prior to clinical diagnosis of cancer. Thus, modification of DNA methylation patterns together with alterations of gene expression may serve as predictive biomarkers for early detection of cancer [29] . Furthermore, epigenetic changes intensify as cancer progresses, and are potentially reversible through pharmacological interventions or genetic manipulation [30, 31] . Therefore, epigenetic biomarkers can also be used for both prognostic and therapeutic purposes.
Investigating the epigenetic basis of bladder carcinogenesis, especially in individuals with known history of exposure to aromatic amines, e.g., specific industry workers or smokers, holds great promise for cancer biomarker discovery [6, 8, 9, 20, [32] [33] [34] . The continuous shedding of bladder cells into the urine offers a unique opportunity for non-invasive surveillance of the epigenetic landscape both before and after clinical manifestation of bladder cancer [34] [35] [36] . The non-invasively obtainable urine specimens from, e.g., occupationally exposed individuals to aromatic amines or smokers, can be analyzed over time to evaluate alterations of the epigenome during the initiation and progression of bladder cancer. Elucidating the underlying mechanisms of bladder carcinogenesis by determining the epigenetic signature of aromatic amines in a readily available surrogate tissue (i.e., urine) will be critical to developing novel diagnostic and/or prognostic biomarkers for bladder cancer.
Over the past decades, an increasing number of methods have been developed to examine the DNA methylation profile at individual loci or on a genome-wide scale in a variety of experimental systems [37] [38] [39] [40] . Here, we described a protocol for the Methylated CpG Island Recovery Assay (MIRA), a sensitive and versatile pull-down assay for enrichment of methylated DNA [41, 42] . This technique is easy to perform and allows recovery of methylated DNA without relying on the use of expensive antibodies. The MIRA (outlined in Fig. 1 ) is based on the ability of the methyl-binding domain (MBD) proteins, the MBD2b/MBD3L1 complex, to specifically bind methylated-CpG dinucleotides [40] [41] [42] . The MIRA-enriched DNA fractions can be used in several downstream applications, including DNA methylation analysis of single loci by real time PCR or bisulfite conversion followed by cloning and DNA sequencing [40] . MIRA is also compatible with high-throughput microarray or next-generation sequencing platforms, e.g., the Illumina Genome Analyzer (MIRA-seq). So far, several versions of MIRA-seq have been developed, all requiring ligation of specific adapters for library construction, DNA sequencing, and sequence read alignment using a reference genome [43] [44] [45] . We and others have successfully applied MIRA to detect aberrant DNA methylation in a variety of tumor types, including human melanoma, lung and breast cancer [41, 46, Tommasi, unpublished data] , immortalized cell lines [47] and mice/cells treated in vivo/in vitro with prototype carcinogens [48, 49] . The MIRA technology is licensed to Active Motif (under U.S. Patent No. 7,425,415), which has developed easy-to-perform kits for MIRA (MethylCollector™ Ultra, Active Motif) and MIRA-seq (MethylCollector™ Ultra-Seq, Active Motif ).
MATERIALS
All reagents must be of molecular biology grade and solutions must be prepared using distilled milliQ water and then autoclaved/filter-sterilized.
Purification of GST-MBD2b and His-MBD3L1 proteins for MIRA
1. GST-tagged MBD2b and histidine-tagged MBD3L1 expression plasmids.
2. LB broth, LB agar, and SOC medium, for bacteriological work [50] . Discard supernatant. 6 . Cell pellets can be processed immediately or kept at -80 o C for several months.
Protein purification
1. Resuspend the cell pellet (from a single falcon tube) in 10 ml of:
-GST-STE buffer containing 100 g/ml lysozyme for GST-MBD2b; -His-STE buffer containing 100 g/ml lysozyme for His-MBD3L1.
2. To each tube, add 100 l of 100 mM PMSF (to a final concentration of 1 mM PMSF) and incubate on ice for 10 min.
3. Lyse bacterial cells by adding 1 ml of 10% N-lauroylsarcosine.
4. Sonicate bacterial lysate until it clears up and loses viscosity.
5. Add 1 ml of 10% Triton-X to the lysate and vortex it for 20 sec. 9. Pellet the beads at 1000 xg for 1 min.
Wash with:
-10 ml of GST-washing buffer for GST-MBD2b; -10 ml of His-washing buffer for His-MBD3L1.
11. Invert tubes several times, then collect beads by centrifugation at 1000 xg for 1 min.
12. Repeat washes two more times. -After dialysis, check protein integrity and concentration on a 10% SDS-PAGE gel using BSA as a standard.
Elution and dialysis
3. Aliquots of purified MBD2b and MBD3L1 proteins can be kept at -20 o C for several months.
Sample preparation for MIRA

DNA isolation
1. High molecular weight genomic DNA can be isolated from cells and tissues using standard phenol/chloroform extraction protocols [50] . Alternatively, commercially available kits, such as the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) can be used.
2. Genomic DNA can be extracted from urine specimens with the Quick-DNA Urine kit (Zymo Research, Irvine, CA).
Fragmentation of genomic DNA
We routinely use a Bioruptor® sonicator (Diagenode, Denville, NJ) to shear genomic DNA to generate 200-to 600-bp fragments (see Note 4).
1. Resuspend 500-700 ng genomic DNA to a final volume of 200 l (with EB or TE buffer).
2. Sonication is performed in apposite tubes using the medium power setting with alternating 30 sec on/30 sec off intervals for a total of 15 min. Avoid overheating.
3. Check an aliquot on 2% agarose gel.
4. Keep 10-20 ng sonicated DNA to use as input (non-MIRA enriched fraction).
MIRA
Binding of MBD proteins to fragmented DNA
1. In a 1.5 ml Eppendorf tube, mix: 1x NEB buffer 2, 0.1% Triton X-100, 0.5g sonicated JM110 DNA, 1 g purified GST-MBD2b, 1 g purified His-MBD3L1, and H 2 O to a final volume of 100 l.
2. Mix by pipetting and pre-incubate at 4 o C for 20 min on a rotating platform. Rotate at a low speed to prevent foaming. This step is required for MBD2b/MBD3L1 complex formation.
3. Add 500-700 ng sonicated genomic DNA to the 100 l binding mix. Adjust final volume to 400 l (with EB buffer).
4. Incubate at 4 o C overnight (or for at least 5 hrs) on a rotating platform.
Washing and pre-blocking of Magne GST beads
1. Add 2.5 l of MagneGST Glutathione Particles into 1 ml of 1x PBS containing 0.1 % Triton X-100 and invert tubes several times.
2. Capture magnetic beads using a magnetic stand and carefully decant the supernatant.
3. Add 1 ml of 1x PBS / 0.1% Triton X-100 into each tube. 4 . Repeat washes for 2-3 times.
5. To decrease non-specific background, pre-block the washed beads with a solution of: 1x NEB buffer 2, 0.1% Triton X-100, 0.5 g sonicated JM110 DNA, and H 2 O up to 400 l. 7. Remove supernatant with the aid of a magnetic stand. 8 . Add 400 l of protein-DNA mix (from 3.3.1.) to the pre-blocked beads.
9. Incubate at 4 o C for ~2 hrs on a rotating platform.
Recovery of the MIRA-enriched DNA fraction
1. Capture the beads with the aid of a magnetic stand and carefully remove the supernatant.
2. Add 800 l of MIRA-washing buffer into the tube and invert 4-5 times. Capture the beads on a magnetic stand. Discard the supernatant.
3. Wash beads (carrying the methylated CpG fraction) for 2-3 times with 1 ml of MIRAwashing buffer. Following beads pulldown, discard supernatant. 4 . Purify the CpG-enriched fraction from the beads with the Qiaquick PCR purification kit according to the manufacturer's instructions. 5 . Elute the CpG-rich fraction from the column with 50 l of EB buffer.
Generation of blunt-ended DNA
Following sonication, DNA fragments must undergo an end-treatment filling step for successful
ligation of the blunt-ended linker adaptor. *Remember to include the input sample (non-MIRA enriched DNA fraction) in parallel at this point. 6. Measure the concentration by a spectrophotometer or Nanodrop.
7. At this point, input and MIRA-enriched DNA from experimental and control samples can be labeled and examined by microarray analysis. Alternatively, samples can be ligated to specific adaptors followed by library construction and analysis on NGS platforms (Fig. 1 ).
NOTES
1. JM110 is a bacterial strain that lacks both DNA adenine methylation (dam) and DNA cytosine methylation (dcm) activities. Purified JM110 DNA is sonicated to an average length of 400-500 bp. Sonicated JM110 DNA is used in the binding reaction to decrease non-specific binding of DNA to MBD proteins and/or beads.
2. 10x NEB 2 buffer (New England Biolabs, Ipswich, MA) can be used as an alternative buffer. Remember to add Triton X-100 to a final concentration of 0.1%.
3. The LM-PCR linker is prepared by combining 50 l of 100 M long oligo with 50 l of 100 M short oligo. The mix (50 M) is incubated for 3 min in a boiling water bath, and allowed to slowly cool down to room temperature. The annealed double-stranded linker is kept in small aliquots at -20C.
4. Alternatively, genomic DNA can be restriction digested with MseI (5'-TTAA-3'), which cuts outside the CpG islands. Different sets of oligos are required to make the linker adaptor. Sonication is preferable to MseI digestion because it does not introduce significant sequence bias.
5. The initial step at 72C is required to fill in the 3' ends of the double-stranded linker adaptor. PCR cycling is monitored in a real-time thermocycler and reactions are stopped immediately before reaching the amplification plateau (14-16 cycles are usually sufficient).
PCR reactions can be scaled down to 10-50 l (final volume). 
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